Asunto(s)
Cirugía Bariátrica , Rivaroxabán , Humanos , Cirugía Bariátrica/efectos adversos , Cirugía Bariátrica/métodos , Rivaroxabán/uso terapéutico , Rivaroxabán/administración & dosificación , Complicaciones Posoperatorias/prevención & control , Anticoagulantes/uso terapéutico , Anticoagulantes/administración & dosificación , Morfolinas/uso terapéutico , Morfolinas/administración & dosificación , Tiofenos/uso terapéutico , Tiofenos/administración & dosificaciónRESUMEN
PURPOSE: Neurokinin 1 receptor antagonists included prophylactic treatment was recommended for patients who receive one-day cisplatin chemotherapy. It is unclear whether the prolonged administration of fosaprepitant is effective for three-day cisplatin-based chemotherapy induced nausea and vomiting (CINV). We aim to explore the prophylactic antiemetic efficacy and safety of two doses of fosaprepitant included regimen in the patients receiving multiple-day cisplatin chemotherapy. METHODS: This randomized, parallel-group, open-labelled study was conducted in nine hospitals between February 2021 and February 2023. Patients diagnosed as lung cancer and chemotherapy naive were screened. Eligible participants were scheduled to be treated with highly emetogenic chemotherapy regimen which including three days of cisplatin. Then they were randomly divided into the experimental group (two doses of fosaprepitant, Group 2DF) and the control group (one dose of fosaprepitant, Group C). The primary endpoints included the safety and the average none CINV days (NCDs). This study was registered on the website of chictr.org.cn, number ChiCTR2100042665. RESULTS: Overall, 204 participants were randomly assigned, and 198 patients were analyzed. No statistical difference in adverse events was found between the two groups. All treatment-related adverse effects for fosaprepitant observed were of grade 1-2. The average NCDs of Group 2DF was significantly more than Group C (18.21 ± 3.40 days vs 16.14 ± 5.20 days, P = 0.001). Furthermore, the better life function score was achieved in Group 2DF according to FLIE questionnaire. CONCLUSION: The administration of two-dose fosaprepitant was safe and more effective than one dose in protecting patients from CINV induced by three-day cisplatin included chemotherapy.
Asunto(s)
Antieméticos , Cisplatino , Morfolinas , Náusea , Vómitos , Humanos , Cisplatino/efectos adversos , Cisplatino/administración & dosificación , Masculino , Femenino , Vómitos/inducido químicamente , Vómitos/prevención & control , Persona de Mediana Edad , Náusea/inducido químicamente , Náusea/prevención & control , Náusea/tratamiento farmacológico , Morfolinas/administración & dosificación , Morfolinas/uso terapéutico , Antieméticos/uso terapéutico , Antieméticos/administración & dosificación , Neoplasias Pulmonares/tratamiento farmacológico , Anciano , Adulto , Protocolos de Quimioterapia Combinada Antineoplásica/efectos adversos , Antineoplásicos/efectos adversos , Antineoplásicos/administración & dosificaciónRESUMEN
Although carboplatin (CBDCA) is classified as a moderately emetogenic agent, the majority of guidelines recommend the use of a neurokinin-1 receptor antagonist in addition to a 5-hydroxytryptamine type 3 receptor antagonist with dexamethasone (DEX) for CBDCA-containing chemotherapy because of its higher emetogenic risk. However, the additional efficacy of aprepitant (APR) in CBDCA-containing treatment remains controversial, and data on multiple-day treatments are limited. Etoposide (ETP) was administered on days 1-3 in the CBDCA + ETP regimen, and it is important to evaluate suitable antiemetic therapy for the regimen. Therefore, we evaluated the efficacy of additional APR in CBDCA + ETP. Patients were divided into two groups and retrospectively evaluated. One was the control group, which was prophylactically administered palonosetron (PALO) and DEX, and the other was the APR group, which received APR orally with PALO and DEX. The primary endpoint was complete response (CR) between the groups. The overall CR rates were 75.0 and 76.4% in the control and APR groups, respectively, with no significant difference (p = 1.00). In the acute phase, it was 88.9 and 97.2%, respectively, and 86.1 and 79.2% in the delayed phase, respectively, without significant differences (p = 0.10 and 0.38, respectively). The incidence and severity of nausea, vomiting, and anorexia were not significantly different between the two groups in the acute and delayed phases. Our findings suggest that combining APR with PALO and DEX does not improve the CR rate in CBDCA + ETP therapy.
Asunto(s)
Antieméticos , Aprepitant , Carboplatino , Dexametasona , Etopósido , Náusea , Palonosetrón , Vómitos , Aprepitant/uso terapéutico , Aprepitant/administración & dosificación , Carboplatino/administración & dosificación , Carboplatino/uso terapéutico , Carboplatino/efectos adversos , Humanos , Dexametasona/administración & dosificación , Dexametasona/uso terapéutico , Palonosetrón/administración & dosificación , Palonosetrón/uso terapéutico , Masculino , Etopósido/administración & dosificación , Etopósido/uso terapéutico , Antieméticos/administración & dosificación , Antieméticos/uso terapéutico , Femenino , Persona de Mediana Edad , Vómitos/inducido químicamente , Vómitos/prevención & control , Anciano , Náusea/inducido químicamente , Náusea/prevención & control , Estudios Retrospectivos , Adulto , Quimioterapia Combinada , Protocolos de Quimioterapia Combinada Antineoplásica/efectos adversos , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Protocolos de Quimioterapia Combinada Antineoplásica/administración & dosificación , Quinuclidinas/administración & dosificación , Quinuclidinas/uso terapéutico , Morfolinas/administración & dosificación , Morfolinas/uso terapéutico , Antineoplásicos/administración & dosificación , Antineoplásicos/uso terapéutico , Antineoplásicos/efectos adversos , Isoquinolinas/administración & dosificación , Isoquinolinas/uso terapéutico , Resultado del TratamientoRESUMEN
PURPOSE: We evaluated the efficacy and safety of antiemetic therapy with olanzapine, a neurokinin-1 receptor antagonist (RA), a 5-hydroxytryptamine-3 (5-HT3) RA, and dexamethasone for preventing chemotherapy-induced nausea and vomiting in patients receiving carboplatin-containing chemotherapy. PATIENTS AND METHODS: Chemotherapy-naïve patients scheduled to receive carboplatin (AUC ≥5) were randomly assigned to receive either olanzapine 5 mg once daily (olanzapine group) or placebo (placebo group) in combination with aprepitant, a 5-HT3 RA, and dexamethasone. The primary end point was the complete response (CR; no vomiting and no rescue therapy) rate in the overall phase (0-120 hours). Secondary end points included the proportion of patients free of nausea and safety. RESULTS: In total, 355 patients (78.6% male, median age 72 years, 100% thoracic cancer), including 175 and 180 patients in the olanzapine and placebo groups, respectively, were evaluated. The overall CR rate was 86.9% in the olanzapine group versus 80.6% in the placebo group. The intergroup difference in the overall CR rate was 6.3% (95% CI, -1.3 to 13.9). The proportions of patients free of chemotherapy-induced nausea in the overall (88.6% in the olanzapine group v 75.0% in the placebo group) and delayed (89.7% v 75.6%, respectively) phases were significantly higher in the olanzapine group than in the placebo group (both P < .001). Somnolence was observed in 43 (24.6%) and 41 (22.9%) patients in the olanzapine and placebo groups, respectively, and no events were grade ≥3 in severity. CONCLUSION: The addition of olanzapine was not associated with a significant increase in the overall CR rate. Regarding the prevention of nausea, adding olanzapine provided better control in patients receiving carboplatin-containing chemotherapy, which needs further exploration.
Asunto(s)
Antieméticos , Aprepitant , Carboplatino , Dexametasona , Náusea , Olanzapina , Vómitos , Humanos , Olanzapina/uso terapéutico , Olanzapina/administración & dosificación , Olanzapina/efectos adversos , Masculino , Carboplatino/efectos adversos , Carboplatino/administración & dosificación , Náusea/inducido químicamente , Náusea/prevención & control , Antieméticos/uso terapéutico , Antieméticos/administración & dosificación , Femenino , Método Doble Ciego , Anciano , Vómitos/inducido químicamente , Vómitos/prevención & control , Persona de Mediana Edad , Dexametasona/uso terapéutico , Dexametasona/administración & dosificación , Aprepitant/uso terapéutico , Aprepitant/administración & dosificación , Anciano de 80 o más Años , Quimioterapia Combinada , Adulto , Benzodiazepinas/efectos adversos , Benzodiazepinas/administración & dosificación , Benzodiazepinas/uso terapéutico , Antineoplásicos/efectos adversos , Morfolinas/uso terapéutico , Morfolinas/administración & dosificación , Neoplasias/tratamiento farmacológico , Antagonistas del Receptor de Neuroquinina-1/uso terapéutico , Antagonistas del Receptor de Neuroquinina-1/administración & dosificaciónRESUMEN
BACKGROUND: Out-of-hospital cardiac arrest (OHCA) complicated by refractory ventricular fibrillation (VF) is associated with poor outcome. Beta-1-receptor selective blockade might overcome refractory VF and improve survival. This trial investigates the efficacy and safety of prehospital landiolol in OHCA and refractory VF. METHODS: In this randomized, double-blind, placebo-controlled pilot trial, patients with OHCA and recurrent or refractory VF (at least 3 defibrillation attempts and last rhythm shockable), pretreated with epinephrine and amiodarone, were allocated to receive add-on treatment with landiolol or placebo. Landiolol was given as a 20 mg bolus infusion. The primary efficacy outcome was time from trial drug infusion to sustained return of spontaneous circulation (ROSC). Safety outcomes included the onset of bradycardia and asystole. RESULTS: A total of 36 patients were enrolled, 19 were allocated to the landiolol group and 17 to the placebo group. Time from trial drug infusion to sustained ROSC was similar between treatment groups (39 min [landiolol] versus 41 min [placebo]). Sustained ROSC was numerically lower in the landiolol group compared with the placebo group (7 patients [36.8%] versus 11 patients [64.7%], respectively). Asystole within 15 min of trial drug infusion occurred significantly more often in the landiolol group than in the placebo group (7 patients [36.8%] and 0 patients [0.0%], respectively). CONCLUSION: In patients with OHCA and refractory VF who are pretreated with epinephrine and amiodarone, add-on bolus infusion of landiolol 20 mg did not lead to a shorter time to sustained ROSC compared with placebo. Landiolol might be associated with bradycardia and asystole.
Asunto(s)
Morfolinas , Paro Cardíaco Extrahospitalario , Urea , Fibrilación Ventricular , Humanos , Masculino , Fibrilación Ventricular/tratamiento farmacológico , Fibrilación Ventricular/complicaciones , Fibrilación Ventricular/etiología , Paro Cardíaco Extrahospitalario/tratamiento farmacológico , Paro Cardíaco Extrahospitalario/complicaciones , Método Doble Ciego , Femenino , Proyectos Piloto , Persona de Mediana Edad , Urea/análogos & derivados , Urea/administración & dosificación , Urea/uso terapéutico , Anciano , Morfolinas/administración & dosificación , Morfolinas/uso terapéutico , Morfolinas/efectos adversos , Antagonistas Adrenérgicos beta/administración & dosificación , Antagonistas Adrenérgicos beta/uso terapéutico , Resultado del Tratamiento , Amiodarona/administración & dosificación , Amiodarona/análogos & derivados , Amiodarona/uso terapéutico , Amiodarona/efectos adversos , Antiarrítmicos/administración & dosificación , Antiarrítmicos/uso terapéutico , Epinefrina/administración & dosificaciónRESUMEN
High pathogenicity avian influenza is an acute zoonotic disease with high mortality in birds caused by a high pathogenicity avian influenza virus (HPAIV). Recently, HPAIV has rapidly spread worldwide and has killed many wild birds, including endangered species. Baloxavir marboxil (BXM), an anti-influenza agent used for humans, was reported to reduce mortality and virus secretion from HPAIV-infected chickens (Gallus domesticus, order Galliformes) at a dosage of ≥2.5 mg/kg when administered simultaneously with viral challenge. Application of this treatment to endangered birds requires further information on potential avian-specific toxicity caused by repeated exposure to BXM over the long term. To obtain information of potential avian-specific toxicity, a 4-wk oral repeated-dose study of BXM was conducted in chickens (n = 6 or 7 per group), which are commonly used as laboratory avian species. The study was conducted in reference to the human pharmaceutical guidelines for nonclinical repeated-dose drug toxicity studies to evaluate systemic toxicity and exposure. No adverse changes were observed in any organs examined, and dose proportional increases in systemic exposure to active pharmaceutical ingredients were noted from 12.5 to 62.5 mg/kg per day. BXM showed no toxicity to chickens at doses of up to 62.5 mg/kg per day, at which systemic exposure was approximately 71 times higher than systemic exposure at 2.5 mg/kg, the reported efficacious dosage amount, in HPAIV-infected chickens. These results also suggest that BXM could be considered safe for treating HPAIV-infected endangered birds due to its high safety margin compared with the efficacy dose. The data in this study could contribute to the preservation of endangered birds by using BXM as a means of protecting biodiversity.
Asunto(s)
Antivirales , Pollos , Dibenzotiepinas , Morfolinas , Piridonas , Triazinas , Animales , Triazinas/administración & dosificación , Dibenzotiepinas/administración & dosificación , Administración Oral , Antivirales/administración & dosificación , Antivirales/farmacología , Morfolinas/administración & dosificación , Morfolinas/farmacología , Piridonas/administración & dosificación , Piridonas/farmacología , Piridinas/administración & dosificación , Tiepinas/administración & dosificación , Tiepinas/farmacología , Masculino , Gripe Aviar/tratamiento farmacológico , Femenino , Oxazinas , Hidroxibutiratos/administración & dosificaciónRESUMEN
HepQuant tests quantify liver function from clearance of deuterium- and 13C-labeled cholates administered either intravenously and orally (SHUNT) or orally (DuO). Hepatic impairment studies have relied on clinical or laboratory criteria like Child-Pugh classification to categorize the degree of hepatic dysfunction. We compared HepQuant tests with Child-Pugh classification in predicting the pharmacokinetics of ampreloxetine. Twenty-one subjects with hepatic impairment (8 Child-Pugh A, 7 Child-Pugh B, and 6 Child-Pugh C), and 10 age- and sex-matched controls were studied. The pharmacokinetics of ampreloxetine were measured after oral administration of a single dose of 10 mg. Disease severity index (DSI), portal-systemic shunting (SHUNT%), hepatic reserve, and hepatic filtration rates (HFRs) were measured from serum samples obtained after intravenous administration of [24-13C]-cholate and oral administration of [2,2,4,4-2H]cholate. Ampreloxetine plasma exposure (AUC0-inf) was similar to controls in Child-Pugh A, increased 1.7-fold in subjects with Child-Pugh B, and 2.5-fold in subjects with Child-Pugh C and correlated with both Child-Pugh score and HepQuant parameters. The variability observed in ampreloxetine exposure (AUC0-inf) in subjects with moderate (Child-Pugh B) and severe hepatic impairment (Child-Pugh C) was explained by HepQuant parameters. Multivariable regression models demonstrated that DSI, SHUNT%, and Hepatic Reserve from SHUNT and DuO were superior predictors of ampreloxetine exposure (AUC0-inf) compared to Child-Pugh score. HepQuant DSI, SHUNT%, and hepatic reserve were more useful predictors of drug exposure than Child-Pugh class for ampreloxetine and thus may better optimize dose recommendations in patients with liver disease. The simple-to-administer, oral-only DuO version of the HepQuant test could enhance clinical utility.
Asunto(s)
Hepatopatías , Morfolinas , Humanos , Masculino , Femenino , Persona de Mediana Edad , Hepatopatías/metabolismo , Anciano , Administración Oral , Morfolinas/farmacocinética , Morfolinas/administración & dosificación , Adulto , Pruebas de Función Hepática/métodos , Índice de Severidad de la Enfermedad , Isótopos de Carbono , Deuterio , Hígado/metabolismo , Alcohol Feniletílico/análogos & derivadosAsunto(s)
Aminopiridinas , Morfolinas , Púrpura Trombocitopénica Idiopática , Piridinas , Humanos , Púrpura Trombocitopénica Idiopática/tratamiento farmacológico , Masculino , Femenino , Persona de Mediana Edad , Enfermedad Crónica , Adulto , Piridinas/uso terapéutico , Piridinas/administración & dosificación , Aminopiridinas/uso terapéutico , Aminopiridinas/administración & dosificación , Morfolinas/uso terapéutico , Morfolinas/administración & dosificación , Anciano , Recurrencia , Quimioterapia Combinada , Oxazinas/uso terapéutico , Oxazinas/administración & dosificación , Pirimidinas/uso terapéutico , Pirimidinas/administración & dosificación , Esteroides/uso terapéutico , Esteroides/administración & dosificación , Proteínas Recombinantes de Fusión/uso terapéutico , Proteínas Recombinantes de Fusión/administración & dosificaciónRESUMEN
Tazemetostat, a novel oral selective inhibitor of enhancer of zeste homolog 2 (EZH2), was approved by the Food and Drug Administration (FDA) in 2020 for use in patients with advanced epithelioid sarcoma or relapsed/refractory (R/R) EZH2-mutated follicular lymphoma. These indications were approved by the FDA trough accelerated approval based on objective response rate and duration of response that resulted from phase 2 clinical trials. Tazemetostat competes with S-adenosylmethionine (SAM) cofactor to inhibit EZH2, reducing the levels of trimethylated lysine 27 of histone 3 (H3K27me3), considered as pharmacodynamic marker. Tazemetostat is orally bioavailable, characterized by rapid absorption and dose-proportional exposure, which is not influenced by coadministration with food or gastric acid reducing agents. It highly distributes in tissues, but with limited access to central nervous system. Tazemetostat is metabolized by CYP3A in the liver to 3 major inactive metabolites (M1, M3, and M5), has a short half-life and is mainly excreted in feces. Drug-drug interactions were shown with moderate CYP3A inhibitors as fluconazole, leading the FDA to recommend a 50% dose reduction, while studies investigating coadministration of tazemetostat with strong inhibitors/inducers are ongoing. No dosage modifications are recommended based on renal or hepatic dysfunctions. Overall, tazemetostat is the first-in-class EZH2 inhibitor approved by the FDA for cancer treatment. Current clinical studies are evaluating combination therapies in patients with several malignancies.
Asunto(s)
Benzamidas , Compuestos de Bifenilo , Interacciones Farmacológicas , Morfolinas , Humanos , Morfolinas/farmacocinética , Morfolinas/farmacología , Morfolinas/administración & dosificación , Compuestos de Bifenilo/farmacocinética , Compuestos de Bifenilo/farmacología , Compuestos de Bifenilo/administración & dosificación , Piridonas/farmacocinética , Piridonas/farmacología , Piridonas/administración & dosificación , Piridonas/uso terapéutico , Proteína Potenciadora del Homólogo Zeste 2/antagonistas & inhibidores , Proteína Potenciadora del Homólogo Zeste 2/metabolismo , Sulfonamidas/farmacocinética , Sulfonamidas/farmacología , Sulfonamidas/administración & dosificación , Antineoplásicos/farmacocinética , Antineoplásicos/farmacología , Antineoplásicos/administración & dosificación , Animales , Organofosfatos/farmacocinética , Organofosfatos/farmacologíaRESUMEN
Abstract Background: Postoperative Nausea and Vomiting (PONV) is a common complication of general anesthesia. Several kinds of antiemetics, including 5-Hydroxytryptamine3 (5-HT3) receptor antagonists, and Neurokinin-1 (NK-1) receptor antagonists have been used to treat PONV. Objectives: To compare the antiemetic effect of NK-1 receptor antagonists, including fosaprepitant. Data sources: Online databases (PubMed, MEDLINE, Scopus, The Cochrane Library databases) were used. Study eligibility criteria, participants, and interventions: Randomized Controlled Trials (RCTs) performed in patients over 18 years with ASA-PS of I‒III, aimed to assess the efficacy of antiemetics including NK-1 receptor antagonists and 5-HT3 receptor antagonists, and compared the incidence of PONV were included. Study appraisal and synthesis methods: All statistical assessments were conducted by a random effect approach, and odds ratios and 95% Confidence Intervals were calculated. Results: Aprepitant 40 mg and 80 mg significantly reduced the incidence of vomiting 0‒24 hours postoperatively (Odds Ratio [OR = 0.40]; 95% Confidence Interval [95% CI 0.30‒0.54]; p < 0.001, and OR = 0.32; 95% CI 0.19‒0.56; p < 0.001). Fosaprepitant could also reduce the incidence of vomiting significantly both 0‒24 and 0‒48 hours postoperatively (OR = 0.07; 95% CI 0.02‒0.24; p < 0.001 and OR = 0.07; 95% CI 0.02‒0.23; p < 0.001). Limitations: Risk factors for PONV are not considered, RCTs using multiple antiemetics are included, RCTs for fosaprepitant is small, and some bias may be present. Conclusions and implications of key findings: Aprepitant and fosaprepitant can be effective prophylactic antiemetics for postoperative vomiting. However, more studies are required for higher-quality meta-analyses. Systematic review registration number: CRD42019120188.
Resumo Histórico: Náusea e Vômito no Pós-Operatório (NVPO) é um evento adverso frequente da anestesia geral. Várias classes de antieméticos, incluindo antagonistas do receptor 5-Hidroxitriptamina3 (5-HT3) e antagonistas do receptor da Neurocinina-1 (NK-1), têm sido utilizados para tratar a NVPO. Objetivo: Comparar o efeito antiemético dos antagonistas do receptor NK-1, incluindo o fosaprepitanto. Fontes de dados: Foram utilizadas bases de dados on-line (PubMed, MEDLINE, Scopus, The Cochrane Library). Critérios de elegibilidade do estudo, participantes e intervenções: Foram incluídos Estudos Clínicos Randomizados (ECR) realizados em pacientes acima de 18 anos classificação ASA I a III, com o objetivo de avaliar a eficácia de antieméticos que incluíssem antagonistas do receptor NK-1 e antagonistas do receptor 5-HT3, e que comparassem a incidência de NVPO. Métodos de avaliação e síntese do estudo: Todas as avaliações estatísticas foram realizadas por abordagem de efeito aleatório e foram calculadas razões de chances e Intervalos de Confiança de 95%. Resultados: As doses de 40 mg e 80 mg de aprepitanto reduziram significantemente a incidência de vômito no período de 0 a 24 horas pós-operatórias (razão de chances [OR = 0,40]; Intervalo de Confiança de 95% [95% IC] 0,30-0,54; p < 0,001 e OR = 0,32; 95% IC 0,19-0,56; p < 0,001). O fosaprepitanto pode também reduzir significantemente a incidência de vômito tanto de 0-24 horas como no período de 0-48 horas pós-operatórias (OR = 0,07; 95% IC 0,02-0,24; p < 0,001 e OR = 0,07; 95% IC 0,02-0,23; p < 0,001). Limitações: Os fatores de risco para NVPO não foram analisados, ECRs usando múltiplos antieméticos foram incluídos, ECRs para fosaprepitanto tinham amostras pequenas, podendo haver algum viés. Conclusões e implicações dos principais achados: Aprepitanto e fosaprepitanto podem ser drogas antieméticas profiláticas efetivas para vômito no pós-operatório. No entanto, são necessários mais estudos para elaboração de meta-análises de melhor qualidade. Número de registro da revisão sistemática: CRD42019120188.
Asunto(s)
Humanos , Náusea y Vómito Posoperatorios/prevención & control , Antagonistas del Receptor de Neuroquinina-1/administración & dosificación , Antieméticos/administración & dosificación , Ensayos Clínicos Controlados Aleatorios como Asunto , Morfolinas/administración & dosificación , Morfolinas/farmacología , Incidencia , Náusea y Vómito Posoperatorios/epidemiología , Antagonistas del Receptor de Serotonina 5-HT3/administración & dosificación , Antagonistas del Receptor de Serotonina 5-HT3/farmacología , Antagonistas del Receptor de Neuroquinina-1/farmacología , Anestesia General/efectos adversos , Anestesia General/métodos , Antieméticos/farmacologíaRESUMEN
This study aimed to investigate the protective effect of salvinorin A on the cerebral pial artery after forebrain ischemia and explore related mechanisms. Thirty Sprague-Dawley rats received forebrain ischemia for 10 min. The dilation responses of the cerebral pial artery to hypercapnia and hypotension were assessed in rats before and 1 h after ischemia. The ischemia reperfusion (IR) control group received DMSO (1 µL/kg) immediately after ischemia. Two different doses of salvinorin A (10 and 20 µg/kg) were administered following the onset of reperfusion. The 5th, 6th, and 7th groups received salvinorin A (20 µg/kg) and LY294002 (10 µM), L-NAME (10 μM), or norbinaltorphimine (norBIN, 1 μM) after ischemia. The levels of cGMP in the cerebrospinal fluid (CSF) were also measured. The phosphorylation of AKT (p-AKT) was measured in the cerebral cortex by western blot at 24 h post-ischemia. Cell necrosis and apoptosis were examined by hematoxylin-eosin staining (HE) and TUNEL staining, respectively. The motor function of the rats was evaluated at 1, 2, and 5 days post-ischemia. The dilation responses of the cerebral pial artery were significantly impaired after ischemia and were preserved by salvinorin A treatment. In addition, salvinorin A significantly increased the levels of cGMP and p-AKT, suppressed cell necrosis and apoptosis of the cerebral cortex and improved the motor function of the rats. These effects were abolished by LY294002, L-NAME, and norBIN. Salvinorin A preserved cerebral pial artery autoregulation in response to hypercapnia and hypotension via the PI3K/AKT/cGMP pathway.
Asunto(s)
Animales , Masculino , Ratas , Arterias Cerebrales/efectos de los fármacos , Isquemia Encefálica/metabolismo , Fosfatidilinositol 3-Quinasas/metabolismo , Diterpenos de Tipo Clerodano/farmacología , Transducción de Señal , Arterias Cerebrales/fisiopatología , Isquemia Encefálica/tratamiento farmacológico , Morfolinas/administración & dosificación , Cromonas/administración & dosificación , Ratas Sprague-Dawley , GMP Cíclico/líquido cefalorraquídeo , GMP Cíclico/metabolismo , NG-Nitroarginina Metil Éster , Diterpenos de Tipo Clerodano/antagonistas & inhibidores , Modelos Animales de Enfermedad , Naltrexona/administración & dosificación , Naltrexona/análogos & derivadosRESUMEN
Introduction: Atrial fibrillation (AF) is the most common arrhythmia. AF increases stroke risk by 5-fold and accounts for 15 percent of stroke. For more than 50 years, vitamin K antagonists were the only available oral anticoagulation. The two major classes of novel oral agents are direct thrombin inhibitors (dabigatran) and factor Xa inhibitors (apixaban or rivaroxaban). These new agents require no routine laboratory monitoring and they are administered in a fixed dose. Method: A non systematic literature review was performed. Results: We performed a critical review of articles about new oral anticoagulants in stroke prevention. We evaluated properties of these agents and we compare efficacy and safety outcomes shown in clinical trials about new oral anticoagulants in AF. Discussion: New oral anticoagulants are at least as good as warfarin at preventing stroke in patients with AF. They seem to be safer than warfarin with significantly less intracranial bleeding. Trials demonstrate dabigatran to be the most effective in decreasing ischemic strokes, apixaban superior to warfarin with statistically lower mortality, and rivaroxaban no worse than warfarin for those with higher stroke risk. Conclussion: New oral anticoagulants have several advantages in comparison with warfarin, but we need further trials to know better the efficacy and safety of these new agents.
Introducción: La fibrilación auricular (FA) es la arritmia más frecuente, se asocia a un riesgo 5 veces mayor de ataque cerebrovascular (ACV), y da cuenta del 15 por ciento de los ACV isquémicos. Por más de medio siglo el tratamiento anticoagulante oral en FA ha estado limitado al uso de antagonistas de la vitamina K. Los nuevos anticoagulantes orales, se clasifican en dos categorías principales: inhibidores de la trombina como el dabigatrán y los inhibidores del factor Xa, como el apixabán y el rivaroxabán. Estos fármacos no requieren monitorización de los niveles de anticoagulación y se administran en dosis fija. Método: Revisión no sistemática de la literatura. Resultados: Se analizan de manera crítica los artículos sobre nuevos anticoagulantes orales en la prevención de ACV. Se evalúan las propiedades de estos nuevos agentes y se comparan los desenlaces de eficacia y de seguridad de los ensayos clínicos de los estos fármacos. Discusión: Los nuevos anticoagulantes orales son al menos tan efectivos que la warfarina en la prevención de ACV cardioembólico en pacientes con FA. Parecen ser más seguros con menor frecuencia de hemorragia intracranial. El dabigatrán es el más efectivo en disminuir el ACV isquémico, el apixabán es superior a la warfarina con una mortalidad significativamente inferior, y el rivaroxabán es no inferior a warfarina para pacientes con alto riesgo de ACV. Conclusión: Los nuevos anticoagulantes orales ofrecen varias ventajas en comparación a warfarina, sin embargo, se requiere se estudios adicionales para conocer más detalladamente su efectividad y perfil de seguridad.
Asunto(s)
Humanos , Accidente Cerebrovascular/prevención & control , Anticoagulantes/administración & dosificación , Fibrilación Atrial/tratamiento farmacológico , Administración Oral , Bencimidazoles/administración & dosificación , Morfolinas/administración & dosificación , Pirazoles/administración & dosificación , Warfarina/administración & dosificación , beta-Alanina/análogos & derivadosRESUMEN
ANTECEDENTES: El síndrome de intestino irritable es una de las principales causas de días perdidos en el trabajo. Como no se conoce hasta ahora ningún tratamiento realmente efectivo, los pacientes acuden con muchos médicos probando todo tipo de medicinas, durante largos períodos de tiempo que duran años. Así, el síndrome de intestino irritable se ha convertido en un serio problema socio-económico que afecta a la familia y al trabajo. METODOS: Se efectuó un estudio aleatorio, doble ciego, controlado con placebo en 40 pacientes consecutivos con síndrome de intestino irritable (edad media: 31.4 +/- 1.8, rango 17-52 años; mujeres). Se administró oralmente bromuro de pinaverio (50 mg) o placebo, tres veces al día con las comidas. RESULTADOS: El bromuro de pinaverio disminuyó la duración del dolor de varias horas a pocos minutos (p<0.05) y mejoró los síntomas recto-anales. No hubieron efectos secundarios. CONCLUSIONES: El bromuro de pinaverio es inocuo y produce beneficio significativo en la calidad de vida del paciente, por lo que puede ser un medicamento valioso en el tratamiento de pacientes con síndrome de intestino irritable.